Drug intelligence / Profile preview

Telitan-H

Development stage
Phase 4
Lead developer
Meddroid Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Telitan-H is a fixed-dose combination oral tablet developed by Meddroid Pharmaceuticals for the management of hypertension. It combines telmisartan, a non-peptide angiotensin II receptor antagonist, with hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland, which inhibits vasoconstriction and the release of aldosterone. Hydrochlorothiazide acts on the renal distal convoluted tubule to inhibit the thiazide-sensitive sodium-chloride transporter (NCC), increasing the excretion of sodium and water. Together, these mechanisms provide a synergistic reduction in blood pressure compared to either component alone.

Brand names
Telitan-H
Other names
telmisartan + hydrochlorothiazidetelmisartan/hydrochlorothiazide
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on Telitan-H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telitan-H.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call